ERBB2 and neoplasm: Finally, the third ongoing clinical trial is also open-label, phase I/II, the first human trial of A166 [19], an anti-HER2 ADC linked to duostatin-5 (a microtubule inhibitor), in relapsed or refractory HER2-positive tumours.